AU2014280055A1 - Obtaining an improved therapeutic ligand - Google Patents

Obtaining an improved therapeutic ligand Download PDF

Info

Publication number
AU2014280055A1
AU2014280055A1 AU2014280055A AU2014280055A AU2014280055A1 AU 2014280055 A1 AU2014280055 A1 AU 2014280055A1 AU 2014280055 A AU2014280055 A AU 2014280055A AU 2014280055 A AU2014280055 A AU 2014280055A AU 2014280055 A1 AU2014280055 A1 AU 2014280055A1
Authority
AU
Australia
Prior art keywords
atom
theta
iota
atoms
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014280055A
Other languages
English (en)
Inventor
Terence Seward Baker
Alastair David Griffiths Lawson
Xiaofeng Liu
Jiye Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2014280055A1 publication Critical patent/AU2014280055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Computing Systems (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
AU2014280055A 2013-06-13 2014-06-13 Obtaining an improved therapeutic ligand Abandoned AU2014280055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1310544.0 2013-06-13
GBGB1310544.0A GB201310544D0 (en) 2013-06-13 2013-06-13 Obtaining an improved therapeutic ligand
PCT/EP2014/062478 WO2014198951A2 (en) 2013-06-13 2014-06-13 Obtaining an improved therapeutic ligand

Publications (1)

Publication Number Publication Date
AU2014280055A1 true AU2014280055A1 (en) 2016-01-28

Family

ID=48914497

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014280055A Abandoned AU2014280055A1 (en) 2013-06-13 2014-06-13 Obtaining an improved therapeutic ligand

Country Status (15)

Country Link
US (2) US20160125124A1 (https=)
EP (1) EP3008648B1 (https=)
JP (1) JP6484612B2 (https=)
KR (1) KR20160019504A (https=)
CN (1) CN105308602B (https=)
AU (1) AU2014280055A1 (https=)
BR (1) BR112015031171A2 (https=)
CA (1) CA2914726A1 (https=)
CL (1) CL2015003591A1 (https=)
GB (1) GB201310544D0 (https=)
HK (1) HK1218579A1 (https=)
MX (1) MX2015016822A (https=)
RU (1) RU2016100234A (https=)
SG (2) SG11201510084TA (https=)
WO (1) WO2014198951A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296732A (en) 2020-03-27 2022-11-01 UCB Biopharma SRL Autonomous knob domain peptides
CN113380320B (zh) * 2021-07-01 2022-03-15 中国海洋大学 基于阳性化合物残基贡献相似度的分子对接结果筛选方法
CN115708166A (zh) * 2021-08-20 2023-02-21 北京望石智慧科技有限公司 一种药物分子设计方法、装置、电子设备及存储介质
CN114530215B (zh) * 2022-02-18 2023-03-28 北京有竹居网络技术有限公司 设计配体分子的方法和装置
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN121712809A (zh) 2023-07-03 2026-03-20 Ucb生物制药有限责任公司 工程化的aav衣壳蛋白
GB202314896D0 (en) 2023-09-28 2023-11-15 UCB Biopharma SRL Knob domain proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5642292A (en) 1992-03-27 1997-06-24 Akiko Itai Methods for searching stable docking models of biopolymer-ligand molecule complex
GB0011818D0 (en) * 2000-05-16 2000-07-05 Inpharmatica Ltd Lead molecule generation
US20020025535A1 (en) 2000-06-15 2002-02-28 Diller David J. Prioritization of combinatorial library screening
AU2001279973A1 (en) 2000-08-21 2002-03-04 Ribotargets Limited Computer-based modelling of ligand/receptor structures
JP2004511803A (ja) * 2000-10-16 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド バニロイド受容体についての改良リガンド結合アッセイ
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
EP1620548A2 (en) 2003-05-07 2006-02-01 Duke University Protein design for receptor-ligand recognition and binding
US20060105390A1 (en) * 2003-10-29 2006-05-18 Yi Zhang Method of characterizing heterogeneity in receptor-ligand interactions and related method of assay signal histogram transformation
JP2005181104A (ja) * 2003-12-19 2005-07-07 Hitachi Ltd 高精度ドッキングスコアリング方法
JP4719223B2 (ja) 2005-03-11 2011-07-06 シュレディンガー エルエルシー 結合親和性を推定するための予測的スコア関数
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US20090006040A1 (en) 2007-05-24 2009-01-01 Peter Hrnciar Systems and Methods for Representing Protein Binding Sites and Identifying Molecules with Biological Activity
EP2216429A4 (en) 2007-11-12 2011-06-15 In Silico Sciences Inc SILICO SCREENING SYSTEM AND SILICO SCREENING METHOD
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
JPWO2010110288A1 (ja) * 2009-03-24 2012-09-27 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f

Also Published As

Publication number Publication date
JP2016527481A (ja) 2016-09-08
CN105308602A (zh) 2016-02-03
CL2015003591A1 (es) 2016-08-05
EP3008648B1 (en) 2023-05-10
US20160125124A1 (en) 2016-05-05
RU2016100234A (ru) 2018-02-06
BR112015031171A2 (pt) 2017-07-25
GB201310544D0 (en) 2013-07-31
RU2016100234A3 (https=) 2018-03-23
SG11201510084TA (en) 2016-01-28
CA2914726A1 (en) 2014-12-18
US20210005277A1 (en) 2021-01-07
JP6484612B2 (ja) 2019-03-13
EP3008648A2 (en) 2016-04-20
SG10201707917UA (en) 2017-10-30
MX2015016822A (es) 2016-04-13
WO2014198951A3 (en) 2015-08-27
CN105308602B (zh) 2019-09-27
HK1218579A1 (zh) 2017-02-24
US11942188B2 (en) 2024-03-26
WO2014198951A2 (en) 2014-12-18
KR20160019504A (ko) 2016-02-19

Similar Documents

Publication Publication Date Title
US11942188B2 (en) Obtaining an improved therapeutic ligand
Adolf-Bryfogle et al. RosettaAntibodyDesign (RAbD): A general framework for computational antibody design
Bahadur et al. The interface of protein-protein complexes: analysis of contacts and prediction of interactions
Brünger et al. Computational challenges for macromolecular structure determination by X-ray crystallography and solution NMRspectroscopy
Keitel et al. Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity
Alber et al. Integrating diverse data for structure determination of macromolecular assemblies
Mao et al. Protein NMR structures refined with Rosetta have higher accuracy relative to corresponding X-ray crystal structures
US20030215877A1 (en) Directed protein docking algorithm
AU2004261198A1 (en) Altered antibodies having improved antigen-binding affinity
Collins et al. CAPRI-Q: The CAPRI resource evaluating the quality of predicted structures of protein complexes
Qu et al. Analysis of binding modes of antigen–antibody complexes by molecular mechanics calculation
Qiao et al. Secondary structure and conformational stability of the antigen residues making contact with antibodies
Lee et al. Identification of ligand templates using local structure alignment for structure-based drug design
DePristo et al. Crystallographic refinement by knowledge-based exploration of complex energy landscapes
US20200126640A1 (en) Computational affinity maturation of antibody libraries using sequence enumeration
JP2012524124A (ja) 回転異性体ライブラリーおよびその使用方法
González-Alemán et al. MCSS-based predictions of binding mode and selectivity of nucleotide ligands
Madan et al. Principles and aspects of molecular docking: A bird’s eye view
Anile et al. Determination of protein structure and dynamics combining immune algorithms and pattern search methods
Collins Dockground Protein Docking Benchmark Sets and Assessment Resource
Hermens Exploring the impact of structure prediction algorithms on structural convergence of antibody repertoires
WO2025219231A1 (en) Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
Kaufmann et al. Small molecule rotamers enable simultaneous optimization of small molecule and protein degrees of freedom in ROSETTALIGAND docking
Zhang et al. Overview of structural bioinformatics
Huang Improving protein docking with binding site prediction

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application